Literature DB >> 26306007

Design of HIV-1 Protease Inhibitors with Amino-bis-tetrahydrofuran Derivatives as P2-Ligands to Enhance Backbone-Binding Interactions: Synthesis, Biological Evaluation, and Protein-Ligand X-ray Studies.

Arun K Ghosh1, Cuthbert D Martyr1, Heather L Osswald1, Venkat Reddy Sheri1, Luke A Kassekert1, Shujing Chen1, Johnson Agniswamy2, Yuan-Fang Wang2, Hironori Hayashi3,4, Manabu Aoki3,5,6, Irene T Weber2, Hiroaki Mitsuya3,4,6.   

Abstract

Structure-based design, synthesis, and biological evaluation of a series of very potent HIV-1 protease inhibitors are described. In an effort to improve backbone ligand-binding site interactions, we have incorporated basic-amines at the C4 position of the bis-tetrahydrofuran (bis-THF) ring. We speculated that these substituents would make hydrogen bonding interactions in the flap region of HIV-1 protease. Synthesis of these inhibitors was performed diastereoselectively. A number of inhibitors displayed very potent enzyme inhibitory and antiviral activity. Inhibitors 25f, 25i, and 25j were evaluated against a number of highly-PI-resistant HIV-1 strains, and they exhibited improved antiviral activity over darunavir. Two high resolution X-ray structures of 25f- and 25g-bound HIV-1 protease revealed unique hydrogen bonding interactions with the backbone carbonyl group of Gly48 as well as with the backbone NH of Gly48 in the flap region of the enzyme active site. These ligand-binding site interactions are possibly responsible for their potent activity.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26306007      PMCID: PMC4765732          DOI: 10.1021/acs.jmedchem.5b00900

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  39 in total

1.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes.

Authors:  Alexander W Schüttelkopf; Daan M F van Aalten
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-07-21

2.  Mitsunobu and related reactions: advances and applications.

Authors:  K C Kumara Swamy; N N Bhuvan Kumar; E Balaraman; K V P Pavan Kumar
Journal:  Chem Rev       Date:  2009-06       Impact factor: 60.622

Review 3.  Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance.

Authors:  Annemarie M J Wensing; Noortje M van Maarseveen; Monique Nijhuis
Journal:  Antiviral Res       Date:  2009-10-22       Impact factor: 5.970

4.  Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.

Authors:  Arun K Ghosh; Perali Ramu Sridhar; Sofiya Leshchenko; Azhar K Hussain; Jianfeng Li; Andrey Yu Kovalevsky; D Eric Walters; Joseph E Wedekind; Valerie Grum-Tokars; Debananda Das; Yasuhiro Koh; Kenji Maeda; Hiroyuki Gatanaga; Irene T Weber; Hiroaki Mitsuya
Journal:  J Med Chem       Date:  2006-08-24       Impact factor: 7.446

5.  In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants by using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors.

Authors:  Yasuhiro Koh; Masayuki Amano; Tomomi Towata; Matthew Danish; Sofiya Leshchenko-Yashchuk; Debananda Das; Maki Nakayama; Yasushi Tojo; Arun K Ghosh; Hiroaki Mitsuya
Journal:  J Virol       Date:  2010-09-01       Impact factor: 5.103

6.  TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates.

Authors:  Sandra De Meyer; Hilde Azijn; Dominique Surleraux; Dirk Jochmans; Abdellah Tahri; Rudi Pauwels; Piet Wigerinck; Marie-Pierre de Béthune
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

7.  Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study.

Authors:  Julio S G Montaner; Viviane D Lima; Rolando Barrios; Benita Yip; Evan Wood; Thomas Kerr; Kate Shannon; P Richard Harrigan; Robert S Hogg; Patricia Daly; Perry Kendall
Journal:  Lancet       Date:  2010-07-16       Impact factor: 79.321

8.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

9.  Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.

Authors:  Yasuhiro Koh; Hirotomo Nakata; Kenji Maeda; Hiromi Ogata; Geoffrey Bilcer; Thippeswamy Devasamudram; John F Kincaid; Peter Boross; Yuan-Fang Wang; Yunfeng Tie; Patra Volarath; Laquasha Gaddis; Robert W Harrison; Irene T Weber; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  6 in total

Review 1.  Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.

Authors:  Arun K Ghosh; Heather L Osswald; Gary Prato
Journal:  J Med Chem       Date:  2016-01-22       Impact factor: 7.446

2.  Structural and binding insights into HIV-1 protease and P2-ligand interactions through molecular dynamics simulations, binding free energy and principal component analysis.

Authors:  Konda Reddy Karnati; Yixuan Wang
Journal:  J Mol Graph Model       Date:  2019-07-18       Impact factor: 2.518

3.  Design, synthesis, biological evaluation and X-ray structural studies of HIV-1 protease inhibitors containing substituted fused-tetrahydropyranyl tetrahydrofuran as P2-ligands.

Authors:  Arun K Ghosh; Cuthbert D Martyr; Luke A Kassekert; Prasanth R Nyalapatla; Melinda Steffey; Johnson Agniswamy; Yuan-Fang Wang; Irene T Weber; Masayuki Amano; Hiroaki Mitsuya
Journal:  Org Biomol Chem       Date:  2015-10-14       Impact factor: 3.876

4.  Novel Protease Inhibitors Containing C-5-Modified bis-Tetrahydrofuranylurethane and Aminobenzothiazole as P2 and P2' Ligands That Exert Potent Antiviral Activity against Highly Multidrug-Resistant HIV-1 with a High Genetic Barrier against the Emergence of Drug Resistance.

Authors:  Yuki Takamatsu; Manabu Aoki; Haydar Bulut; Debananda Das; Masayuki Amano; Venkata Reddy Sheri; Ladislau C Kovari; Hironori Hayashi; Nicole S Delino; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

5.  Nature Inspired Molecular Design: Stereoselective Synthesis of Bicyclic and Polycyclic Ethers for Potent HIV-1 Protease Inhibitors.

Authors:  Arun K Ghosh; Margherita Brindisi
Journal:  Asian J Org Chem       Date:  2018-06-08       Impact factor: 3.319

6.  Structural studies of antiviral inhibitor with HIV-1 protease bearing drug resistant substitutions of V32I, I47V and V82I.

Authors:  Shrikant Pawar; Yuan-Fang Wang; Andres Wong-Sam; Johnson Agniswamy; Arun K Ghosh; Robert W Harrison; Irene T Weber
Journal:  Biochem Biophys Res Commun       Date:  2019-05-12       Impact factor: 3.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.